“35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022”, YHCĐ, vol. 65, no. CĐ 3 - Bệnh viện Phổi Trung ương, May 2024, doi: 10.52163/yhc.v65iCD3.1132.